{"title":"Broadening our view of power in clinician–patient relationships in oncology","authors":"Laura Nimmon, Gary Rodin, Elizabeth C Smyth","doi":"10.1016/s1470-2045(25)00333-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00333-x","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ling-Long Tang, Cheng-Long Huang, Shao-Jun Lin, Quynh-Thu Le, Brian O'Sullivan, Sue S Yom, Shao Hui Huang, Annie W Chan, Nancy Lee, Jian-Ji Pan, Michael Benedict A Mejia, Yong Chan Ahn, Kenneth C W Wong, Lachlan McDowell, Ester Orlandi, Jeppe Friborg, Yu-Pei Chen, Koichi Yasuda, Takeshi Kodaira, Alexander C Whitley, Jun Ma
{"title":"Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas","authors":"Ling-Long Tang, Cheng-Long Huang, Shao-Jun Lin, Quynh-Thu Le, Brian O'Sullivan, Sue S Yom, Shao Hui Huang, Annie W Chan, Nancy Lee, Jian-Ji Pan, Michael Benedict A Mejia, Yong Chan Ahn, Kenneth C W Wong, Lachlan McDowell, Ester Orlandi, Jeppe Friborg, Yu-Pei Chen, Koichi Yasuda, Takeshi Kodaira, Alexander C Whitley, Jun Ma","doi":"10.1016/s1470-2045(25)00326-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00326-2","url":null,"abstract":"The Chinese Society for Therapeutic Radiology Oncology, the Chinese Anti-Cancer Association, the Chinese Society of Clinical Oncology, Head and Neck Cancer International Group, the European Society for Radiotherapy and Oncology, and the American Society for Radiation Oncology jointly developed evidence-based guidelines and a contouring atlas for primary target volume delineation for radiotherapy in nasopharyngeal carcinoma. The guidelines systematically address three crucial challenges: margin design of clinical target volumes; target volume delineation after induction chemotherapy; and low-risk clinical target volume delineation based on local stepwise extension patterns. Based on a comprehensive systematic review and critical appraisal by an international multidisciplinary panel of 50 nasopharyngeal carcinoma specialists from 17 countries and regions, these guidelines are in keeping with advances in nasopharyngeal carcinoma diagnosis and treatment, embodying contemporary treatment concepts, and elaborating on the differences in practice. These guidelines aim to support global clinical practice in radiotherapy target volume delineation, substantially enhancing homogeneity and reducing variability in nasopharyngeal carcinoma target delineation.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Niccolò Lombardi, Roberto Franchini, Joana Berberi, Giovanni Lodi
{"title":"Oral lesion as the first sign of disseminated sarcomatoid carcinoma","authors":"Niccolò Lombardi, Roberto Franchini, Joana Berberi, Giovanni Lodi","doi":"10.1016/s1470-2045(25)00432-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00432-2","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>NL followed the clinical case, collected the clinical data, and wrote the manuscript. RF followed the patient during diagnosis. JB followed the patient during diagnosis. GL reviewed the manuscript and followed the clinical case. Written informed consent to publication was obtained.</section></section><section><section><h2>Declaration of interests</h2>We declare no competing interests.</section></section>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reflecting on the patient-reported outcomes from the EV-302 trial","authors":"Jun Li, Honglin Hu","doi":"10.1016/s1470-2045(25)00374-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00374-2","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144928551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aiping Zhou, Pengfei Shen, Juan Li, Wang Qu, Zengjun Wang, Xiubao Ren, Yuan Li, Shusuan Jiang, Gang Li, Yu Zeng, Weijun Qin, Jin Wu, Peng Chen, Fangjian Zhou, Hongqian Guo, Zhigang Ji, Yongquan Wang, Zhisong He, Jitao Wu, Benkang Shi, Xinan Sheng
{"title":"First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial","authors":"Aiping Zhou, Pengfei Shen, Juan Li, Wang Qu, Zengjun Wang, Xiubao Ren, Yuan Li, Shusuan Jiang, Gang Li, Yu Zeng, Weijun Qin, Jin Wu, Peng Chen, Fangjian Zhou, Hongqian Guo, Zhigang Ji, Yongquan Wang, Zhisong He, Jitao Wu, Benkang Shi, Xinan Sheng","doi":"10.1016/s1470-2045(25)00343-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00343-2","url":null,"abstract":"<h3>Background</h3>The underexplored potential of PD-L1 blockade in advanced renal cell carcinoma highlights an urgent need for novel agents. This trial aimed to compare benmelstobart (a novel PD-L1 inhibitor) plus anlotinib with sunitinib as first-line treatment for advanced renal cell carcinoma.<h3>Methods</h3>ETER100 was a multicentre, randomised, open-label, phase 3 trial conducted at 37 medical sites in China. We included patients aged 18–80 years, who had previously untreated, advanced, clear-cell renal cell carcinoma, and an Eastern Cooperative Oncology Group performance status of 0 or 1. We randomly assigned (1:1) patients to receive either benmelstobart (intravenous, 1200 mg, once every 3 weeks) plus anlotinib (oral, 12 mg, once daily for the first 2 weeks of a 3-week cycle) or sunitinib (oral, 50 mg, once daily for the first 4 weeks of a 6-week cycle) until disease progression, unacceptable toxicity, investigator's decision, or patient withdrawal. Randomisation was done centrally with stratified block randomisation (block size 4) and stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk. The primary endpoint was progression-free survival as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumours version 1.1 in the full analysis set (ie, randomly assigned patients who received at least one dose of study drug without the violation of key inclusion criteria) and per-protocol set (ie, randomly assigned patients who received at least one cycle of protocol treatment without major protocol violations and had at least one efficacy assessment). In this Article, we report the results of a prespecified interim analysis. This ongoing study, closed to recruitment, is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT04523272</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>.<h3>Findings</h3>Between Aug 25, 2020, and Feb 6, 2023, we assessed 687 patients for eligibility, 531 (77%) of whom were randomly assigned to receive either benmelstobart plus anlotinib (266 [50%] patients) or sunitinib (265 [50%] patients). 527 (99%) patients were included in the full analysis set (263 [50%] patients who received benmelstobart plus anlotinib and 264 [50%] who received sunitinib). All patients were Chinese (400 [76%] men and 127 [24%] women), with a median age of 60 years (IQR 54–67). As of the cutoff date (Jan 31, 2024), the median follow-up was 22·8 months (IQR 15·2–29·7). In the full analysis set, median progression-free survival was significantly longer with benmelstobart plus anlotinib than with","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"162 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chloe Gui, Justin Z Wang, Vikas Patil, Alexander P Landry, Olivia Singh, Pedro Castelo-Branco, Uri Tabori, Kenneth Aldape, Felix Behling, Jill S Barnholtz-Sloan, Craig Horbinski, Ghazaleh Tabatabai, Andrew Ajisebutu, Jeff Liu, Zeel Patel, Rebeca Yakubov, Ramneet Kaloti, Yosef Ellenbogen, Christopher Wilson, Aaron Cohen-Gadol, Gelareh Zadeh
{"title":"Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study","authors":"Chloe Gui, Justin Z Wang, Vikas Patil, Alexander P Landry, Olivia Singh, Pedro Castelo-Branco, Uri Tabori, Kenneth Aldape, Felix Behling, Jill S Barnholtz-Sloan, Craig Horbinski, Ghazaleh Tabatabai, Andrew Ajisebutu, Jeff Liu, Zeel Patel, Rebeca Yakubov, Ramneet Kaloti, Yosef Ellenbogen, Christopher Wilson, Aaron Cohen-Gadol, Gelareh Zadeh","doi":"10.1016/s1470-2045(25)00267-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00267-0","url":null,"abstract":"<h3>Background</h3><em>TERT</em> promoter mutation is a rare biomarker in meningiomas associated with aberrant <em>TERT</em> expression and reduced progression-free survival. Although high <em>TERT</em> expression is characteristic of tumours with <em>TERT</em> promoter mutations, it has also been observed in tumours with wildtype <em>TERT</em> promoters. This study aimed to investigate the prevalence and prognostic association of <em>TERT</em> expression in meningiomas.<h3>Methods</h3>This multi-institutional cohort study retrospectively collected clinical and molecular data from 1241 meningiomas surgically resected between Jan 1, 2000, and Dec 31, 2024, at Toronto Western Hospital, Canada (n=380; discovery cohort) and external institutions in Canada, Germany, and the USA (n=861; validation cohort). All patients were aged 18 years and older. <em>TERT</em> promoter mutation and <em>TERT</em> expression were determined by Sanger and bulk RNA sequencing. The primary outcomes were <em>TERT</em> expression (presence or absence) in meningiomas with and without <em>TERT</em> promoter mutations, and the difference in progression-free survival between tumours expressing <em>TERT</em> and those not expressing <em>TERT</em>. Survival analysis was assessed using Cox regression and Kaplan–Meier analysis.<h3>Findings</h3>Between Jan 1, 2000, and Dec 31, 2024, clinical demographics and tumour characteristics were collected. Median follow-up was 6·2 years (IQR 1·7–12·5) in the discovery cohort and 3·3 years (1·3–3·8) in the validation cohort. 777 (65·8%) of 1181 patients with sex data in the overall cohort were female; 404 (34·2%) were male. <em>TERT</em> was expressed in 157 (28·7%) of 547 wildtype <em>TERT</em> promoter meningiomas and in 193 (32·0%) of 604 overall with RNA data. <em>TERT</em> expression overall conferred an intermediate progression-free survival, shorter than that in patients with <em>TERT</em>-negative tumours but longer than in those with <em>TERT</em> promoter mutations. In the discovery cohort, median progression-free survival was 3·2 years (95% CI 1·7–6·5) in patients with wildtype <em>TERT</em> promoter tumours expressing <em>TERT</em>, 16·0 years (7·1 to not reached; p=0·0021) in patients with <em>TERT</em>-negative wildtype <em>TERT</em> promoter tumours, and 1·6 years (0·9 to not reached; p=0·039) in patients with <em>TERT</em> promoter mutations. These findings were replicated in the validation cohort. Within each WHO grade, <em>TERT</em> expression conferred a progression-free survival equivalent to <em>TERT</em>-negative meningiomas of one grade higher. Grade 1 tumours with <em>TERT</em> expression had a progression-free survival similar to <em>TERT</em>-negative grade 2 tumours (median not reached [95% CI 16·0 to not reached] <em>vs</em> 8·2 years [95% CI 4·5 to not reached]; p=0·59). Grade 2 tumours with <em>TERT</em> expression had a similar progression-free survival to <em>TERT</em>-negative grade 3 tumours (median 3·6 years ","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hope against the odds","authors":"Paul Adepoju","doi":"10.1016/s1470-2045(25)00143-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00143-3","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
